


Strategy to overcome tumors' resistance to immunotherapy generates promising clinical trial results

November 18 2021



Credit: Unsplash/CC0 Public Domain

Immune checkpoint inhibitors can boost the immune system's response to tumor cells, but the medications tend to be ineffective against certain cancers, especially colorectal and pancreatic cancers. A new clinical trial

led by investigators at Massachusetts General Hospital (MGH) indicates that combining radiation with immune checkpoint inhibitors may be an effective strategy to combat these resistant cancers.

Preclinical studies have shown that low-dose radiation can create a "tumor vaccine" environment that triggers an [immune response](#) when stimulated with the [immune checkpoint inhibitors](#) nivolumab and ipilimumab—which have different targets—in resistant cancers. As reported in *Nature Cancer*, researchers tested this strategy in a single-arm phase II trial of 40 patients with [colorectal cancer](#) and 25 patients with pancreatic cancer. In patients who received the planned treatment of radiation + nivolumab + ipilimumab, 37% of patients with colorectal cancer and 29% of patients with pancreatic cancer experienced responses to the therapy (with complete or partial responses or stable disease that did not progress).

"This is an impressive clinical result given that historically, these cancers respond in the low single digit percentage range," says senior author David T. Ting, MD, associate clinical director for innovation at the MGH Cancer Center and an associate professor of medicine at Harvard Medical School. He added that new information indicates that improved timing of the sequencing of radiation therapy with immunotherapy may enhance efficacy that merits further investigation.

The investigators noted that analyses of cancer biopsies taken before treatment revealed that tumors that responded to the triple therapy tended to have higher expression of certain viral sequences that are found normally in the human genome. These sequences belong to a retrovirus called HERV-K.

"HERV-K may be a potential marker of response to this immunotherapy regimen, which can be used for future studies to tailor treatments to individual patients," says Ting. Studies that look into the potential role of

these viral sequences in cancer biology are also warranted.

More information: David Ting, Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial, *Nature Cancer* (2021).

[DOI: 10.1038/s43018-021-00269-7](https://doi.org/10.1038/s43018-021-00269-7).

www.nature.com/articles/s43018-021-00269-7

Provided by Massachusetts General Hospital

Citation: Strategy to overcome tumors' resistance to immunotherapy generates promising clinical trial results (2021, November 18) retrieved 3 July 2023 from

<https://medicalxpress.com/news/2021-11-strategy-tumors-resistance-immunotherapy-clinical.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.